Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 56 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Swedish Orphan Biovitrum's reported carbon emissions
In 2023, Swedish Orphan Biovitrum (Sobi) reported total carbon emissions of approximately 124,565,000 kg CO2e. This figure includes 904,000 kg CO2e from Scope 1 emissions, 648,000 kg CO2e from Scope 2 emissions, and a significant 124,565,000 kg CO2e from Scope 3 emissions. Sobi has set ambitious climate commitments, aiming to reduce its operational greenhouse gas (GHG) footprint by 50% from a 2016 baseline for both Scope 1 and Scope 2 emissions by 2025. Additionally, the company has committed to achieving net zero emissions for Scope 1 and Scope 2 by 2030. Furthermore, Sobi has established a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 37.8% by FY2029, using FY2023 as the base year. The company also aims for 65% of its suppliers, by spend, to have science-based targets by FY2029, reinforcing its commitment to sustainable practices across its supply chain. These initiatives reflect Sobi's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 435,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 1,157,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 1,031,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
